Partnerships and Commercial Strategy
Q Chip has two pathways to commercialisation:
1. Q Chip’s developing biogenerics pipeline, comprising of Q-Leuprolide and Q-Octreotide, will be available for out-licensing.
2. Custom Product Development; Q Chip is actively seeking research collaborations with API originator companies, whose novel biopharmaceutical therapies require parenteral sustained-release vehicles or formulations. Our flexible platform allows fine tuning of microsphere size and final drug release profile; with inter-batch uniformity, and extremely low solvent residuals.
If you would like to discuss licensing Q-Sphera or accessing the MicroPlant technology please contact Dr Nanette Bartram:
E: nanette.bartram@q-chip.com
T: +44 7872 078 277 or +44 29 2048 0180